| Drug Name | ( Invokana® ( CANAGLIFLOZIN |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
patient guide
Safety communication
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
Risk of diabetic ketoacidosis Risk of Fournier´s gangrene (necrotising fasciitis of the perineum) with Sodium-Glucose-Co-Transporter 2 inhibitor Risk of Rare but Serious Infection in the Genital Area with Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Advice on the Risk of Lower Limb Amputation Primarily of the Toe during treatment with canagliflozin |
| patient guide |
|
| safety communication |
|
| Dear Healthcare provider letter DHPC |
|